IL23A and asthma: Contrary to this evidence supporting a role for IL-23 in the pathogenesis of obese asthma, Brightling et al. [126] reported that, as compared to placebo, administration of risankizumab, a humanized IgG1 monoclonal antibody, which binds to the p19 subunit of IL-23, decreased the time to the first asthma worsening after treatment commenced, increased the annualized rate of asthma worsening, and had no effect on FEV1 or sputum eosinophils or neutrophils [127].